At Fosun Health, esophageal cancer diagnosis must answer four critical questions: Is it cancer? How deeply has it invaded the esophageal wall? Has it spread to lymph nodes or distant organs? What is its molecular "fingerprint"? Our integrated pathway delivers all answers within days:
We perform magnifying endoscopy with NBI (Narrow Band Imaging), Lugol's iodine staining, or chromoendoscopy to visualize subtle mucosal changes invisible to standard scopes. Targeted biopsy confirms histology (squamous cell carcinoma vs. adenocarcinoma), differentiation grade, and invasion depth.
The most accurate tool for T-staging. EUS reveals how deeply the tumor has penetrated the esophageal wall layers and whether nearby mediastinal lymph nodes are involved—directly determining whether endoscopic resection (ESD/EMR), minimally invasive surgery, or multimodal therapy is appropriate.
Evaluates local tumor extent, regional lymph nodes, and distant metastases (liver, lung, bone, adrenal glands).
Detects occult metastases and distant lymph node involvement that CT may miss, critical for accurate staging and treatment planning.
Using NGS (Next-Generation Sequencing), we analyze HER2, EGFR, PD-L1, MSI/dMMR, CLDN18.2, and over 300 cancer-related genes. For esophageal adenocarcinoma, this determines eligibility for trastuzumab or trastuzumab deruxtecan (T-DXd). For ESCC, PD-L1 expression guides immunotherapy selection, while EGFR amplification may indicate sensitivity to EGFR-targeted agents. This ensures your treatment is matched to your tumor's unique biology.
